246 related articles for article (PubMed ID: 27739357)
21. LpxC inhibitors: a patent review (2010-2016).
Kalinin DV; Holl R
Expert Opin Ther Pat; 2017 Nov; 27(11):1227-1250. PubMed ID: 28742403
[TBL] [Abstract][Full Text] [Related]
22. Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.
McAllister LA; Montgomery JI; Abramite JA; Reilly U; Brown MF; Chen JM; Barham RA; Che Y; Chung SW; Menard CA; Mitton-Fry M; Mullins LM; Noe MC; O'Donnell JP; Oliver RM; Penzien JB; Plummer M; Price LM; Shanmugasundaram V; Tomaras AP; Uccello DP
Bioorg Med Chem Lett; 2012 Nov; 22(22):6832-8. PubMed ID: 23046961
[TBL] [Abstract][Full Text] [Related]
23. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens.
Tomaras AP; McPherson CJ; Kuhn M; Carifa A; Mullins L; George D; Desbonnet C; Eidem TM; Montgomery JI; Brown MF; Reilly U; Miller AA; O'Donnell JP
mBio; 2014 Sep; 5(5):e01551-14. PubMed ID: 25271285
[TBL] [Abstract][Full Text] [Related]
24. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa.
Mdluli KE; Witte PR; Kline T; Barb AW; Erwin AL; Mansfield BE; McClerren AL; Pirrung MC; Tumey LN; Warrener P; Raetz CR; Stover CK
Antimicrob Agents Chemother; 2006 Jun; 50(6):2178-84. PubMed ID: 16723580
[TBL] [Abstract][Full Text] [Related]
25. Molecular recognition by Escherichia coli UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase is modulated by bound metal ions.
Hernick M; Fierke CA
Biochemistry; 2006 Dec; 45(49):14573-81. PubMed ID: 17144651
[TBL] [Abstract][Full Text] [Related]
26. A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin.
McClerren AL; Endsley S; Bowman JL; Andersen NH; Guan Z; Rudolph J; Raetz CR
Biochemistry; 2005 Dec; 44(50):16574-83. PubMed ID: 16342948
[TBL] [Abstract][Full Text] [Related]
27. LpxC (UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase) inhibitors: A long path explored for potent drug design.
Kumar Pal S; Kumar S
Int J Biol Macromol; 2023 Apr; 234():122960. PubMed ID: 36565833
[TBL] [Abstract][Full Text] [Related]
28. Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC.
Lemaître N; Liang X; Najeeb J; Lee CJ; Titecat M; Leteurtre E; Simonet M; Toone EJ; Zhou P; Sebbane F
mBio; 2017 Jul; 8(4):. PubMed ID: 28743813
[TBL] [Abstract][Full Text] [Related]
29. Lead optimization of 2-hydroxymethyl imidazoles as non-hydroxamate LpxC inhibitors: Discovery of TP0586532.
Ushiyama F; Takashima H; Matsuda Y; Ogata Y; Sasamoto N; Kurimoto-Tsuruta R; Ueki K; Tanaka-Yamamoto N; Endo M; Mima M; Fujita K; Takata I; Tsuji S; Yamashita H; Okumura H; Otake K; Sugiyama H
Bioorg Med Chem; 2021 Jan; 30():115964. PubMed ID: 33385955
[TBL] [Abstract][Full Text] [Related]
30. Uridine-based inhibitors as new leads for antibiotics targeting Escherichia coli LpxC.
Barb AW; Leavy TM; Robins LI; Guan Z; Six DA; Zhou P; Hangauer MJ; Bertozzi CR; Raetz CR
Biochemistry; 2009 Apr; 48(14):3068-77. PubMed ID: 19256534
[TBL] [Abstract][Full Text] [Related]
31. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase of Escherichia coli is a zinc metalloenzyme.
Jackman JE; Raetz CR; Fierke CA
Biochemistry; 1999 Feb; 38(6):1902-11. PubMed ID: 10026271
[TBL] [Abstract][Full Text] [Related]
32. LpxC inhibition: Potential and opportunities with carbohydrate scaffolds.
Amudala S; Sumit ; Aidhen IS
Carbohydr Res; 2024 Mar; 537():109057. PubMed ID: 38402732
[TBL] [Abstract][Full Text] [Related]
33. N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay.
Furuya T; Shapiro AB; Comita-Prevoir J; Kuenstner EJ; Zhang J; Ribe SD; Chen A; Hines D; Moussa SH; Carter NM; Sylvester MA; Romero JAC; Vega CV; Sacco MD; Chen Y; O'Donnell JP; Durand-Reville TF; Miller AA; Tommasi RA
Bioorg Med Chem; 2020 Dec; 28(24):115826. PubMed ID: 33160146
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and structure-activity relationship evaluation of novel LpxC inhibitors as Gram-negative antibacterial agents.
Ding S; Dai RY; Wang WK; Cao Q; Lan LF; Zhou XL; Yang YS
Bioorg Med Chem Lett; 2018 Jan; 28(2):94-102. PubMed ID: 29233653
[TBL] [Abstract][Full Text] [Related]
35. Crystal structure of LpxC, a zinc-dependent deacetylase essential for endotoxin biosynthesis.
Whittington DA; Rusche KM; Shin H; Fierke CA; Christianson DW
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8146-50. PubMed ID: 12819349
[TBL] [Abstract][Full Text] [Related]
36. Structure of the metal-dependent deacetylase LpxC from Yersinia enterocolitica complexed with the potent inhibitor CHIR-090 .
Cole KE; Gattis SG; Angell HD; Fierke CA; Christianson DW
Biochemistry; 2011 Jan; 50(2):258-65. PubMed ID: 21171638
[TBL] [Abstract][Full Text] [Related]
37. Refined solution structure of the LpxC-TU-514 complex and pKa analysis of an active site histidine: insights into the mechanism and inhibitor design.
Coggins BE; McClerren AL; Jiang L; Li X; Rudolph J; Hindsgaul O; Raetz CR; Zhou P
Biochemistry; 2005 Feb; 44(4):1114-26. PubMed ID: 15667205
[TBL] [Abstract][Full Text] [Related]
38. Activation of Escherichia coli UDP-3-O-[(R)-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase by Fe2+ yields a more efficient enzyme with altered ligand affinity.
Hernick M; Gattis SG; Penner-Hahn JE; Fierke CA
Biochemistry; 2010 Mar; 49(10):2246-55. PubMed ID: 20136146
[TBL] [Abstract][Full Text] [Related]
39. Bacterial Zinc Metalloenzyme Inhibitors: Recent Advances and Future Perspectives.
Di Leo R; Cuffaro D; Rossello A; Nuti E
Molecules; 2023 May; 28(11):. PubMed ID: 37298854
[TBL] [Abstract][Full Text] [Related]
40. Treatment of human challenge and MDR strains of Neisseria gonorrhoeae with LpxC inhibitors.
John CM; Feng D; Jarvis GA
J Antimicrob Chemother; 2018 Aug; 73(8):2064-2071. PubMed ID: 29726994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
